Soliris (Eculizumab) – Monoclonal Antibody Therapy for Rare Blood & Immune Disorders

What Is Soliris?

Soliris (eculizumab) is a breakthrough monoclonal antibody therapy developed by Alexion Pharmaceuticals. It works as a complement inhibitor, blocking part of the immune system (the complement cascade) that can cause uncontrolled inflammation and destruction of blood cells.

Approved by the FDA, EMA, and other global regulators, Soliris is one of the most advanced treatments for rare, life‑threatening conditions including:

• Paroxysmal nocturnal hemoglobinuria (PNH)
• Atypical hemolytic uremic syndrome (aHUS)
• Generalized myasthenia gravis (gMG)
• Neuromyelitis optica spectrum disorder (NMOSD)

How Soliris Works

• Complement inhibition: Soliris binds to complement protein C5, preventing its cleavage into C5a and C5b.
• Prevents cell destruction: Stops the formation of the membrane attack complex (MAC), which damages red blood cells.
• Reduces inflammation: Limits immune overactivation in autoimmune and rare disorders.
• Improves quality of life: Reduces symptoms, hospitalizations, and disease progression.

Indications

1. PNH (Paroxysmal Nocturnal Hemoglobinuria):
   • Prevents hemolysis (destruction of red blood cells).
   • Reduces risk of blood clots and organ damage.
2. aHUS (Atypical Hemolytic Uremic Syndrome):
   • Controls complement‑mediated thrombotic microangiopathy.
   • Improves kidney function and reduces dialysis dependence.
3. Generalized Myasthenia Gravis (gMG):
   • Approved for patients positive for anti‑acetylcholine receptor antibodies.
   • Improves muscle strength and reduces fatigue.
4. Neuromyelitis Optica Spectrum Disorder (NMOSD):
   • Prevents relapses in patients positive for anti‑aquaporin‑4 antibodies.
   • Reduces risk of blindness and paralysis.

Administration

• Route: Intravenous infusion.
• Initial dosing: Weekly for the first 5 weeks.
• Maintenance dosing: Every 2 weeks thereafter.
• Duration: Long‑term therapy under specialist supervision.

Benefits of Soliris

• Life‑saving therapy: First FDA‑approved complement inhibitor.
• Reduces hospitalizations: Proven to lower relapse rates and complications.
• Improves survival: Extends life expectancy in PNH and aHUS patients.
• Global recognition: Approved in UK, EU, Canada, Australia, and many other countries.

Safety & Precautions

• Boxed warning: Increased risk of meningococcal infections; vaccination required before treatment.
• Common side effects: Headache, nausea, infections, back pain, diarrhea.
• Monitoring: Regular blood tests and infection surveillance.
• Contraindications: Not for patients with unresolved meningococcal infection.

Global Availability

Prime Equine Meds ensures secure and reliable access to Soliris across multiple regions:

• UK & Ireland – Licensed distribution with fast delivery.
• Canada & USA – FDA‑approved therapy available.
• Australia & New Zealand – Safe import channels for rare disease treatment.
• Europe (Germany, France, Spain, Portugal, Switzerland, etc.) – Multilingual support and EU‑compliant supply chain.

Why Choose Prime Equine Meds?

• Authenticity Guaranteed: Genuine Soliris sourced from trusted suppliers.
• Worldwide Shipping: Covering major European countries, UK, Canada, and Australia.
• Expert Support: Guidance on safe handling, dosage, and administration.
• Customer Confidence: Transparent policies, secure checkout, and responsive service.

Soliris the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, and neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. SOLIRIS is not indicated for the treatment of patients with Shiga-toxin E. coli-related hemolytic uremic syndrome (STEC-HUS). It is not known if SOLIRIS is safe and effective in children with PNH, or gMG, or NMOSD.
SOLIRIS is a prescription medicine used to treat:

patients with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).
adults and children with a disease called atypical Hemolytic Uremic Syndrome (aHUS). SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
adults with a disease called neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.
It is not known if SOLIRIS is safe and effective in children with PNH, gMG, or NMOSD.

IMPORTANT SAFETY INFORMATION
What is the most important information I should know about SOLIRIS?
SOLIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections.

SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.
You must receive meningococcal vaccines at least 2 weeks before your first dose of SOLIRIS if you are not vaccinated.
If your doctor decided that urgent treatment with SOLIRIS is needed, you should receive meningococcal vaccination as soon as possible.
If you have not been vaccinated and SOLIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations.
If you had a meningococcal vaccine in the past, you might need additional vaccination. Your doctor will decide if you need additional vaccination.
Meningococcal vaccines reduce but do not prevent all meningococcal infections. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, and eyes sensitive to light.
Your doctor will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 3 months after your last SOLIRIS dose. It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly.

Soliris (eculizumab) is a groundbreaking monoclonal antibody therapy that has transformed the treatment of PNH, aHUS, gMG, and NMOSD. By targeting the complement system, it prevents life‑threatening complications and improves patient outcomes worldwide. Prime Equine Meds is committed to providing safe, authentic, and accessible Soliris globally, ensuring patients with rare disorders receive the highest standard of care.